The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia
Open accessAbstract
Histone deacetylases (HDACs) are a key component of the epigenetic machinery regulating gene expression, and behave as oncogenes in several cancer types, spurring the development of HDAC inhibitors (HDACi) as anticancer drugs. This review discusses new results regarding the role of HDACs in cancer and the effect of HDACi on tumour cells, focusing on haematological malignancies, particularly acute myeloid leukaemia. Histone deacetylases may have opposite roles at different stages of tumour progression and in different tumour cell sub-populations (cancer stem cells), highlighting the importance of investigating these aspects for further improving the clinical use of HDACi in treating cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Haberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
Huang, M., Ye, Y., Chen, Sr., Chai, Jr., Lu, J., Zhoa, L., Gu, L., & Wang, Z. (1988) · Blood · doi:10.1182/blood.v72.2.567.567 · Cited by 2,445
Evolution of the Cancer Stem Cell Model
Kreso, A., & Dick, J. E. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.02.006 · Cited by 2,224
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Self-citationFraga, M. F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K., et al. (2005) · Nature Genetics · doi:10.1038/ng1531 · Cited by 1,923
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes
Wang, Z., Zang, C., Cui, K., Schones, D. E., Barski, A., Peng, W., & Zhao, K. (2009) · Cell · doi:10.1016/j.cell.2009.06.049 · Cited by 1,344
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men
Yang, X.-J., & Seto, E. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2346 · Cited by 1,230
All-trans-Retinoic Acid in Acute Promyelocytic Leukemia
Tallman, M. S., Andersen, J. W., Schiffer, C. A., Appelbaum, F. R., Feusner, J. H., Ogden, A., Shepherd, L., Willman, C., Bloomfield, C. D., Rowe, J. M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371501 · Cited by 1,073
Wagner, G. R., & Payne, R. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.486753 · Cited by 494
Clinical Toxicities of Histone Deacetylase Inhibitors
Subramanian, S., Bates, S. E., Wright, J. J., Espinoza-Delgado, I., & Piekarz, R. L. (2010) · Pharmaceuticals · doi:10.3390/ph3092751 · Cited by 386
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
Nasr, R., Guillemin, M.-C., Ferhi, O., Soilihi, H., Peres, L., Berthier, C., Rousselot, P., Robledo-Sarmiento, M., Lallemand-Breitenbach, V., Gourmel, B., et al. (2008) · Nature Medicine · doi:10.1038/nm.1891 · Cited by 354
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition
Ropero, S., Fraga, M. F., Ballestar, E., Hamelin, R., Yamamoto, H., Boix-Chornet, M., Caballero, R., Alaminos, M., Setien, F., Paz, M. F., et al. (2006) · Nature Genetics · doi:10.1038/ng1773 · Cited by 290
Saji, S., Kawakami, M., Hayashi, S.-I., Yoshida, N., Hirose, M., Horiguchi, S.-I., Itoh, A., Funata, N., Schreiber, S. L., Yoshida, M., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208646 · Cited by 258
Müller, B. M., Jana, L., Kasajima, A., Lehmann, A., Prinzler, J., Budczies, J., Winzer, K.-J., Dietel, M., Weichert, W., & Denkert, C. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-215 · Cited by 256
Histone deacetylases and epigenetic therapies of hematological malignancies
Mercurio, C., Minucci, S., & Pelicci, P. G. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.02.010 · Cited by 134
Self-citationA dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance
Santoro, F., Botrugno, O. A., Zuffo, R. D., Pallavicini, I., Matthews, G. M., Cluse, L. A., Barozzi, I., Senese, S., Fornasari, L., Moretti, S., et al. (2013) · Blood · doi:10.1182/blood-2012-10-461988 · Cited by 132
Self-citationHistone deacetylase inhibitors and genomic instability
Éot-Houllier, G., Fulcrand, G., Magnaghi-Jaulin, L., & Jaulin, C. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.06.005 · Cited by 132
Impairment of p53 acetylation, stability and function by an oncogenic transcription factor
Insinga, A., Monestiroli, S., Ronzoni, S., Carbone, R., Pearson, M. A., Pruneri, G., Viale, G., Appella, E., Pelicci, P. G., & Minucci, S. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600109 · Cited by 120
Self-citationHistone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer
Botrugno, O. A., Santoro, F., & Minucci, S. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.027 · Cited by 114
Self-citationKebede, A. F., Schneider, R., & Daujat, S. (2014) · FEBS Journal · doi:10.1111/febs.13047 · Cited by 89
Divergent roles of HDAC1 and HDAC2 in the regulation of epidermal development and tumorigenesis
Winter, M., Moser, M., Meunier, D., Fischer, C., Machat, G., Mattes, K., Lichtenberger, B. M., Brunmeir, R., Weissmann, S., Murko, C., et al. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.243 · Cited by 72
Rincón‐Arano, H., Halow, J. M., Delrow, J. J., Parkhurst, S. M., & Groudine, M. T. (2012) · Cell · doi:10.1016/j.cell.2012.11.009 · Cited by 66
Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies
Matthews, G. M., Mehdipour, P., Cluse, L. A., Falkenberg, K. J., Wang, E., Roth, M., Santoro, F., Vidacs, E., Stanley, K. L., House, C. M., et al. (2015) · Blood · doi:10.1182/blood-2015-03-632984 · Cited by 65
Self-citationLeiva, M., Moretti, S., Soilihi, H., Pallavicini, I., Peres, L., Mercurio, C., Dal Zuffo, R., Minucci, S., & de Thé, H. (2012) · Leukemia · doi:10.1038/leu.2012.39 · Cited by 58
Self-citationValente, S., & Mai, A. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.877446 · Cited by 49
New Insights into the Connection Between Histone Deacetylases, Cell Metabolism, and Cancer
Chiaradonna, F., Cirulli, C., Palorini, R., Votta, G., & Alberghina, L. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.5854 · Cited by 16
Cited by
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
Metabolic reprogramming and epigenetic modifications on the path to cancer
Sun, L., Zhang, H., & Gao, P. (2022) · Protein & Cell · doi:10.1007/s13238-021-00846-7 · Cited by 770
Fellows, R., Denizot, J., Stellato, C., Cuomo, A., Jain, P., Stoyanova, E., Balázsi, S., Hajnády, Z., Liebert, A., Kazakevych, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02651-5 · Cited by 568
Epigenetic mechanisms in breast cancer therapy and resistance
Garcia-Martinez, L., Zhang, Y., Nakata, Y., Chan, H. L., & Morey, L. (2021) · Nature Communications · doi:10.1038/s41467-021-22024-3 · Cited by 458
Milazzo, G., Mercatelli, D., Di Muzio, G., Triboli, L., De Rosa, P., Perini, G., & Giorgi, F. M. (2020) · Genes · doi:10.3390/genes11050556 · Cited by 423
Metadata
- Authors
- Ceccacci, E., & Minucci, S.
- Venue
- British Journal of Cancer
- Published
- 2016-02-23
- Volume
- 114
- Issue
- 6
- Pages
- 605-611
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2276640786
- Cited by
- 253
- References
- 30
- FWCI
- 16.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.